| | This Amendment No. 1 (this "Amendment") amends and supplements the Schedule 13D filed with the Securities and Exchange Commission on March 23, 2026 (the "Original Schedule 13D" and, as amended and supplemented by this Amendment, this "Schedule 13D") by Matthew George (the "Reporting Person") relating to the common stock, par value $0.0001 per share (the "Common Stock"), of Merlin, Inc. (the "Issuer"). Except as specifically amended and supplemented by this Amendment, the Original Schedule 13D remains in full force and effect. Capitalized terms used but not defined herein have the meanings given to them in the Original Schedule 13D.
Item 4 of the Original Schedule 13D is hereby amended and supplemented by adding the following:
Transition Agreement
On November 18, 2026, the Reporting Person and the Issuer entered into a Transition Agreement (the "Transition Agreement"), pursuant to which, effective as of November 18, 2026 (the "Transition Date"), the Reporting Person ceased to serve as the Chief Executive Officer of the Issuer and Chairman of the Issuer's Board of Directors (the "Board") and resigned from all of his positions with the Issuer and its affiliates, including all director, officer, employee and fiduciary positions, except for his position as Founder and Advisor. On November 19, 2026, the Issuer announced the transition and the appointment of Dr. Robert H. Smith as Interim Chief Executive Officer and Chairman of the Board, and filed a Current Report on Form 8-K with respect thereto.
Under the Transition Agreement, the Reporting Person will serve as Founder and Advisor, as an independent consultant reporting to the Board, from and including the Transition Date until the first anniversary of the Transition Date, unless earlier terminated (such period, the "Advisory Period"), for a monthly services fee of $6,250, and will provide transition assistance and advice as reasonably requested by the Board, not to exceed 15 hours per month. The Transition Agreement provides for separation payments and benefits in satisfaction of the Issuer's Executive Severance Plan, including a cash payment of $937,500 payable in substantially equal installments over the 18 months following the Transition Date, a cash payment of $625,000 in respect of the Reporting Person's 2026 target annual bonus, and an 18-month subsidy towards the cost of continued medical insurance benefits under the Issuer's group health plan in accordance with the Consolidated Omnibus Budget Reconciliation Act of 1986, as amended (the "COBRA Subsidy"), as well as certain additional payments equal to $937,500 and six times the monthly COBRA Subsidy, in the event a change in control of the Issuer occurs within specified periods following the Transition Date, in each case subject to the Reporting Person's execution and non-revocation of a general release of claims.
Treatment of Equity Awards
Pursuant to the Transition Agreement, the Reporting Person's outstanding stock options and restricted stock units did not vest in connection with his termination of employment and instead continue to vest during the Advisory Period pursuant to the terms of the applicable award agreements and equity incentive plans. Upon a termination of the Reporting Person's service as Founder and Advisor for any reason other than by the Issuer for cause or by the Reporting Person prior to the first anniversary of the Transition Date (other than as a result of the Issuer's material breach), the then-remaining unvested portion of each option and restricted stock unit award will vest; if such service is terminated by the Reporting Person prior to the first anniversary of the Transition Date (other than as a result of the Issuer's material breach), the portion of each award that would have vested had his service continued through the first anniversary will vest. In addition, if a change in control of the Issuer occurs on or prior to the first anniversary of the Transition Date while the Reporting Person is continuing to provide services as Founder and Advisor, all unvested options and restricted stock units then outstanding will vest. Vested options remain outstanding and exercisable until their initial expiration dates.
Standstill
Under the Transition Agreement, for a period of three years following the Transition Date (the "Standstill Period"), the Reporting Person has agreed, subject to specified exceptions, not to, among other things: acquire or seek to acquire any securities of the Issuer (other than upon the exercise or vesting of equity awards or pursuant to stock splits, stock dividends or similar corporate transactions initiated by the Issuer); propose or seek to effect any tender or exchange offer, merger, business combination, recapitalization, restructuring or other extraordinary transaction involving the Issuer; make or participate in any solicitation of proxies, or seek to advise or influence any person with respect to the voting of any voting securities of the Issuer (other than in favor of proposals supported by the Board); form or participate in any "group" within the meaning of Section 13(d) of the Securities Exchange Act of 1934 with respect to any voting securities of the Issuer; act to seek to control, change or influence the management, Board or policies of the Issuer; commence or support any derivative action in the name of the Issuer or any class action against the Issuer; engage in any short sale or similar transaction with respect to securities of the Issuer; or publicly disclose any intention, plan or arrangement inconsistent with the foregoing. The standstill does not prevent the Reporting Person from selling any voting securities owned by him, provided such sales are permissible under applicable federal and state securities laws, and the Issuer has confirmed that no contractual restrictions between the Issuer and the Reporting Person apply to any such sale. While the Reporting Person is an affiliate of the Issuer, the Issuer has agreed not to unreasonably withhold or delay its approval of any sale of the Issuer's shares by the Reporting Person that complies with securities laws and to reasonably cooperate with any such sale.
Voting Proxy
Under the Transition Agreement, the Reporting Person has agreed to vote, or cause to be voted, at any meeting of stockholders held during the Standstill Period, all shares of the Issuer's stock held directly or indirectly by him, whether now owned or hereafter acquired, over which he has voting control, in accordance with the disinterested stockholders of the Issuer on any proposal, and has granted the Issuer an irrevocable proxy to so vote such shares during the Standstill Period. The standstill and voting provisions described above terminate upon a material breach of the Transition Agreement by the Issuer that is not cured within 15 days after written notice from the Reporting Person.
The Transition Agreement also contains non-competition, non-solicitation, non-interference, non-disparagement, confidentiality, cooperation and intellectual property provisions, and provisions regarding indemnification of the Reporting Person by the Issuer and continuation of directors' and officers' liability insurance coverage. The foregoing description of the Transition Agreement does not purport to be complete and is qualified in its entirety by reference to the full text of the Transition Agreement, which is filed as Exhibit 99.3 to this Schedule 13D and incorporated herein by reference.
General
The Reporting Person intends to review his investments in the Issuer on a continuing basis. Subject to the terms of the Transition Agreement (including the standstill and voting provisions described above) and applicable securities laws, the Reporting Person may retain or sell all or a portion of the securities he holds in the open market or in privately negotiated transactions. Except as set forth in this Schedule 13D (including the arrangements under the Transition Agreement described herein), the Reporting Person does not currently have any plans or proposals that relate to, or would result in, any of the matters listed in Items 4(a)-(j) of Schedule 13D; the standstill provisions of the Transition Agreement restrict the Reporting Person from pursuing many such matters during the Standstill Period. |